|
Randomized, two-way, two-period, single oral dose, open-label, crossover, bioequivalence study to compare Glibil tablets (5 mg glibenclamide) Produced by Hikma / Jordan versus Daonil® tablets (5 mg glibenclamide) Produced Sanofi-Aventis / Germany, in healthy subjects under fed condition.
|
Ongoing
|
Glibil
|
BE
|
17-2017
|
Saudi Ajal
|
|
Randomized, two-way, two-period, single oral dose, open-label, crossover, bioequivalence study to compare Diatab tablets (5 mg glibenclamide) Produced by SPIMACO / KSA versus Daonil® tablets (5 mg glibenclamide) Produced by Sanofi- Aventis / Germany, in healthy subjects under fed condition.
|
Ongoing
|
Diatab
|
BE
|
18-2017
|
Saudi Ajal
|
|
"DIREGL07563 RATIONAL studyAn obseRvationAl registry To assess urInary albumin evOlution in Saudi hyperteNsive patients with the current treatment local ALgorithm "
|
Ongoing
|
APROVEL / Irbesartan
|
4
|
3
|
King Abdulaziz University Hospital (Jeddah)
|
|
Grazoprevir/Elbasvir For Treatment Of Hepatitis C Virus Genotype 4 Post Kidney Transplant
|
Ongoing
|
Zepatier
|
4
|
2171009
|
King Faisal Specialist Hospital and Research Center (Riyadh)
|
|
Randomized, two-way, two-period, single oral dose, open-label, crossover, bioequivalence study to compare Solifenacin succinate film-coated tablets (10 mg solifenacin succinate) versus Vesicare® film-coated tablets (10 mg solifenacin succinate), in healthy subjects under fasting condition.
|
Ongoing
|
solifenacin succinate
|
BE
|
Feb-17
|
Saudi Ajal
|
|
A phase III randomized open-label multi-center study of ruxolitinib vs. best available therapy in patients with corticosteroid-refractory chronic graft versus host disease after allogenic stem cell transplantation
|
Ongoing
|
Ruxolitinib (INC424) (Jakavi)
|
3
|
CINC424D2301
|
King Faisal Specialist Hospital and Research Center (Riyadh)
|
|
Phase II/III randomized multicentre study comparing neoadjuvant chemoradiotherapy followed by consolidation chemotherapy to neoadjuvant chemoradiotherapy alone in non-metastatic rectal cancer patients.
|
Ongoing
|
Capecitabine / oxaliplatin / FOLINIC Acid / FLUOROURACIL
|
2
|
IRB#17-329 version2
|
King Abdullah Medical City (Makkah)
|
|
<p style="text-align: justify;">Long-term Safety and Efficacy Study of Ferriprox® for the Treatment of<br />Transfusional Iron Overload in Patients with Sickle Cell Disease<br />or Other Anemias</p>
|
Ongoing
|
Deferiprone
|
3b
|
LA38-EXT
|
Aseer Central Hospital
|
|
Cholecalciferol supplementation in critically ill patients with severe vitamin D deficiency in intensive care unit – a randomized controlled trial
|
Ongoing
|
VITAMIN D3 (CHOLECALCIFEROL)
|
3
|
IRB#16-252, V2
|
King Abdullah Medical City (Makkah)
|
|
A phase III randomized open-label multi-center study of ruxolitinib vs. best available therapy in patients with corticosteroid-refractory acute graft vs. host disease after allogenic stem cell transplantation
|
Ongoing
|
Ruxolitinib (INC424) (Jakavi)
|
3
|
CINC424C2301
|
King Faisal Specialist Hospital and Research Center (Riyadh)
|
